ImmuPharma PLC
AIM:IMM
United Kingdom / Healthcare / Pharmaceuticals
Exchange Data
Hide this widget
Price
2.65 GBX
Day change
-0.02 (-0.75%)
52-week range
0.85 - 7.26
6:35 PM - Closed
Summary of ImmuPharma PLC
Hide this widget
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics a...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Years
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| IMM | Peers | Sector | |
|---|---|---|---|
Market Cap | 11.036 M | 19.346 M | 48.503 M |
Price % of 52 Week High | Premium | 40.4% | 61.6% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | Premium | -5.2% | -0.7% |
1 Year Price Total Return | 7.1% | -35.9% | -12.5% |
Beta (5 Year) | 2.59 | 0.68 | 0.64 |
In the News
Hide this widget
No data available
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for ImmuPharma is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for ImmuPharma PLC
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 3 days ago |
| 10Y Historical FinancialsView Updated 3 days ago |
| 5Y Historical FinancialsView Updated 3 days ago |
| Price / Book MultiplesView Updated 22 hours ago |
| Price / Sales MultiplesView Updated 22 hours ago |
| EV / Revenue MultiplesView Updated 22 hours ago |
| CAPM WACC ModelView Updated 1 day ago |
| 10Y DCF EBITDA ExitView Updated 22 hours ago |
| 10Y DCF Revenue ExitView Updated 22 hours ago |
| 10Y DCF Growth ExitView Updated 22 hours ago |
| 5Y DCF EBITDA ExitView Updated 22 hours ago |
| 5Y DCF Revenue ExitView Updated 22 hours ago |
| 5Y DCF Growth ExitView Updated 22 hours ago |
| Earnings Power ValueView Updated 22 hours ago |
| EV / EBIT MultiplesView Updated 22 hours ago |
| EV / EBITDA MultiplesView Updated 22 hours ago |
| P/E MultiplesView Updated 22 hours ago |
Historical Financials
Full Financials
Hide this widget
| (GBP in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Jun-24 | Jun-23 | Jun-24 |
| Income Statement | |||||
| Revenue | (0.07) | 0.03 | |||
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | (2.91) | (3.03) | (2.56) | (0.61) | (0.37) |
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (2.45) | (1.36) | (1.59) | (0.33) | (0.44) |
Analyst Notes
April 3, 2025
Hide this widget